Verve Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERV research report →
About the company
Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver.
- CEO
- Sekar Kathiresan
- IPO
- 2021
- Employees
- 274
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $994.04M
- P/E
- -4.72
- P/S
- 30.74
- P/B
- 1.91
- EV/EBITDA
- -4.02
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -707.23%
- Net Margin
- -614.59%
- ROE
- -36.36%
- ROIC
- -37.19%
- Revenue
- $32.33M · 174.98%
- Net Income
- $-198,709,000 · 0.68%
- EPS
- $-2.36 · 24.36%
- Op Income
- $-228,660,000
- FCF YoY
- -1.63%
- 52W High
- $11.40
- 52W Low
- $2.87
- 50D MA
- $8.21
- 200D MA
- $6.45
- Beta
- 2.24
- Avg Volume
- 5.72M
Get TickerSpark's AI analysis on VERV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 25, 25 | GV 2017 GP, L.L.C. | other | 1,800,000 |
| Jul 25, 25 | MacLean Michael F | sell | 136,139 |
| Jul 25, 25 | MacLean Michael F | sell | 42,200 |
| Jul 25, 25 | Yeshwant Krishna | sell | 136,139 |
| Jul 25, 25 | Yeshwant Krishna | sell | 42,200 |
| Jul 25, 25 | Yeshwant Krishna | other | 1,800,000 |
| Jul 25, 25 | Dorval Allison | sell | 75,000 |
| Jul 25, 25 | Dorval Allison | other | 13,280 |
| Jul 25, 25 | Dorval Allison | sell | 1,875 |
| Jul 25, 25 | Dorval Allison | sell | 180,000 |
Our VERV coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VERV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.